Eli Lilly granted compassionate-use access to its experimental obesity drug for a single patient
Eli Lilly’s experimental obesity drug retatrutide, which has shown bariatric-surgery levels of weight loss and is still awaiting FDA approval, was provided to a 79-year-old patient in April through the FDA’s compassionate-use program, according to STAT. That pathway is typically reserved for patients with serious, immediately life-threatening conditions — an unusual fit for an obesity treatment.
What drew scrutiny is who was involved. STAT reported the request attracted the attention of top federal health officials, suggesting the recipient was well connected, and sources who described the arrangement requested anonymity citing fear of reprisal. The episode raises the question of whether a single patient received early access to a sought-after drug on the basis of influence rather than medical necessity.
Compassionate-use decisions normally turn on a clinician’s request and the manufacturer’s willingness to supply a drug, with FDA sign-off; granting that access to one elderly patient for obesity, and the involvement of senior officials, is what makes the case notable. Lilly did not provide a statement in the report.